Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

3.95

Today's Change

+0.05 (1.28%)

Day's Change

3.91 - 3.99

Trading Volume

76,431

Overview

Market Cap

1 Billion

Shares Outstanding

320 Million

Avg Volume

1,527,289

Avg Price (50 Days)

4.96

Avg Price (200 Days)

5.65

PE Ratio

-26.33

EPS

-0.15

Earnings Announcement

26-Feb-2025

Previous Close

3.90

Open

3.95

Day's Range

3.91 - 3.99

Year Range

2.22 - 8.975

Trading Volume

77,136

Price Change Highlight

1 Day Change

1.28%

5 Day Change

1.54%

1 Month Change

-13.19%

3 Month Change

-39.79%

6 Month Change

-37.10%

Ytd Change

-2.71%

1 Year Change

70.26%

3 Year Change

395.29%

5 Year Change

163.33%

10 Year Change

163.33%

Max Change

163.33%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment